News headlines about Celator Pharmaceuticals (NASDAQ:CPXX) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celator Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.8594935543496 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

COPYRIGHT VIOLATION NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-celator-pharmaceuticals-cpxx-stock-price/1473299.html.

About Celator Pharmaceuticals

Celator Pharmaceuticals, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.

Insider Buying and Selling by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Receive News & Ratings for Celator Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.